Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Apr 3

PMID 33805973

Citations 18

Authors

Chee Wai Fhu

Azhar Ali

Affiliations

Soon will be listed here.

Abstract

The ubiquitin proteasome system (UPS) governs the non-lysosomal degradation of oxidized, damaged, or misfolded proteins in eukaryotic cells. This process is tightly regulated through the activation and transfer of polyubiquitin chains to target proteins which are then recognized and degraded by the 26S proteasome complex. The role of UPS is crucial in regulating protein levels through degradation to maintain fundamental cellular processes such as growth, division, signal transduction, and stress response. Dysregulation of the UPS, resulting in loss of ability to maintain protein quality through proteolysis, is closely related to the development of various malignancies and tumorigenesis. Here, we provide a comprehensive general overview on the regulation and roles of UPS and discuss functional links of dysregulated UPS in human malignancies. Inhibitors developed against components of the UPS, which include U.S. Food and Drug Administration FDA-approved and those currently undergoing clinical trials, are also presented in this review.

Citing Articles

TarKG: a comprehensive biomedical knowledge graph for target discovery.

Zhou C, Cai C, Huang X, Wu S, Yu J, Wu J Bioinformatics. 2024; 40(10).

PMID: 39392404 PMC: 11513019. DOI: 10.1093/bioinformatics/btae598.

Nano-Proteolysis Targeting Chimeras (Nano-PROTACs) in Cancer Therapy.

Song Y, Dong Q, Ni Y, Xu X, Chen C, Chen W Int J Nanomedicine. 2024; 19:5739-5761.

PMID: 38882545 PMC: 11180470. DOI: 10.2147/IJN.S448684.

Anticancer drugs: How to select small molecule combinations?.

Nussinov R, Yavuz B, Jang H Trends Pharmacol Sci. 2024; 45(6):503-519.

PMID: 38782689 PMC: 11162304. DOI: 10.1016/j.tips.2024.04.012.

Modeling reveals the strength of weak interactions in stacked-ring assembly.

Lagunes L, Briggs K, Martin-Holder P, Xu Z, Maurer D, Ghabra K Biophys J. 2024; 123(13):1763-1780.

PMID: 38762753 PMC: 11267433. DOI: 10.1016/j.bpj.2024.05.015.

Isoform alterations in the ubiquitination machinery impacting gastrointestinal malignancies.

Kasturirangan S, Nancarrow D, Shah A, Lagisetty K, Lawrence T, Beer D Cell Death Dis. 2024; 15(3):194.

PMID: 38453895 PMC: 10920915. DOI: 10.1038/s41419-024-06575-z.

References

Fahmidehkar M, Shafiee S, Eftekhar E, Mahbudi L, Seghatoleslam A . Induction of cell proliferation, clonogenicity and cell accumulation in S phase as a consequence of human UBE2Q1 overexpression. Oncol Lett. 2016; 12(3):2169-2174. PMC: 4998499. DOI: 10.3892/ol.2016.4860. View

Yeh C, Bellon M, Pancewicz-Wojtkiewicz J, Nicot C . Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia patients. Proc Natl Acad Sci U S A. 2016; 113(24):6731-6. PMC: 4914202. DOI: 10.1073/pnas.1601537113. View

Lee H, Lee S, Hur S, Seo J, Kwon J . Stabilization and targeting of INO80 to replication forks by BAP1 during normal DNA synthesis. Nat Commun. 2014; 5:5128. DOI: 10.1038/ncomms6128. View

Brichory F, Beer D, Le Naour F, Giordano T, Hanash S . Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res. 2001; 61(21):7908-12. View

Gill H, Yim R, Pang H, Lee P, Chan T, Hwang Y . Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation. Cancer Med. 2020; 9(10):3371-3382. PMC: 7221314. DOI: 10.1002/cam4.2865. View

Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S . Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors. J Med Chem. 2015; 58(16):6348-58. DOI: 10.1021/acs.jmedchem.5b00810. View

Hu M, Li P, Li M, Li W, Yao T, Wu J . Crystal structure of a UBP-family deubiquitinating enzyme in isolation and in complex with ubiquitin aldehyde. Cell. 2003; 111(7):1041-54. DOI: 10.1016/s0092-8674(02)01199-6. View

Carbone M, Ferris L, Baumann F, Napolitano A, Lum C, Flores E . BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012; 10:179. PMC: 3493315. DOI: 10.1186/1479-5876-10-179. View

Clague M, Heride C, Urbe S . The demographics of the ubiquitin system. Trends Cell Biol. 2015; 25(7):417-26. DOI: 10.1016/j.tcb.2015.03.002. View

10.

Byrne A, McLaren R, Mason P, Chai L, Dufault M, Huang Y . Knockdown of human deubiquitinase PSMD14 induces cell cycle arrest and senescence. Exp Cell Res. 2009; 316(2):258-71. DOI: 10.1016/j.yexcr.2009.08.018. View

11.

Rawat A, Gopal G, Selvaluxmy G, Rajkumar T . Inhibition of ubiquitin conjugating enzyme UBE2C reduces proliferation and sensitizes breast cancer cells to radiation, doxorubicin, tamoxifen and letrozole. Cell Oncol (Dordr). 2013; 36(6):459-67. DOI: 10.1007/s13402-013-0150-8. View

12.

Ma J, Lu Y, Zhang S, Li Y, Huang J, Yin Z . β-Trcp ubiquitin ligase and RSK2 kinase-mediated degradation of FOXN2 promotes tumorigenesis and radioresistance in lung cancer. Cell Death Differ. 2018; 25(8):1473-1485. PMC: 6113220. DOI: 10.1038/s41418-017-0055-6. View

13.

Ciechanover A . Intracellular protein degradation: From a vague idea thru the lysosome and the ubiquitin-proteasome system and onto human diseases and drug targeting. Best Pract Res Clin Haematol. 2017; 30(4):341-355. DOI: 10.1016/j.beha.2017.09.001. View

14.

Zhang Y, Shi J, Liu X, Feng L, Gong Z, Koppula P . BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat Cell Biol. 2018; 20(10):1181-1192. PMC: 6170713. DOI: 10.1038/s41556-018-0178-0. View

15.

Zhang H, Han B, Lu H, Zhao Y, Chen X, Meng Q . USP22 promotes resistance to EGFR-TKIs by preventing ubiquitination-mediated EGFR degradation in EGFR-mutant lung adenocarcinoma. Cancer Lett. 2018; 433:186-198. DOI: 10.1016/j.canlet.2018.07.002. View

16.

Bajetta E, Buzzoni R, Valagussa P, Bonadonna G . Mitoxantrone: an active agent in refractory non-Hodgkin's lymphomas. Am J Clin Oncol. 1988; 11(2):100-3. View

17.

Kim S, Ramasamy K, Bouamar H, Lin A, Jiang D, Aguiar R . MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci U S A. 2012; 109(20):7865-70. PMC: 3356650. DOI: 10.1073/pnas.1200081109. View

18.

Kuznetsov J, Aguero T, Owens D, Kurtenbach S, Field M, Durante M . BAP1 regulates epigenetic switch from pluripotency to differentiation in developmental lineages giving rise to BAP1-mutant cancers. Sci Adv. 2019; 5(9):eaax1738. PMC: 6750916. DOI: 10.1126/sciadv.aax1738. View

19.

Miranda M, Sorkin A . Regulation of receptors and transporters by ubiquitination: new insights into surprisingly similar mechanisms. Mol Interv. 2007; 7(3):157-67. DOI: 10.1124/mi.7.3.7. View

20.

Renatus M, Parrado S, DArcy A, Eidhoff U, Gerhartz B, Hassiepen U . Structural basis of ubiquitin recognition by the deubiquitinating protease USP2. Structure. 2006; 14(8):1293-302. PMC: 7126176. DOI: 10.1016/j.str.2006.06.012. View